Previous 10 | Next 10 |
GT Biopharma (NASDAQ:GTBP), a clinical-stage immunooncology company, has named Manu Ohri as its Chief Financial Officer (CFO) with immediate effect. Ohri has over 25 years of management, finance and public accounting experience and has served as CFO for multiple public companies. He was previ...
GT Biopharma Appoints Manu Ohri as Chief Financial Officer PR Newswire BRISBANE, Calif. , Feb. 18, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Com...
GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference PR Newswire BRISBANE, Calif. , Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics base...
GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) PR Newswire BRISBANE, Calif. , Jan. 6, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative t...
Preclinical data on GT Biopharma's (NASDAQ:GTBP) GTB-5550 found that the candidate induces natural killer cell activation against a broad spectrum of tumors expressing B7-H3. Shares are up more than 12% in premarket trading. The company also found that a dual camelid bispecific...
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 - GTB-5550, which harbors wild-type IL-15, and BiKE display broad activity against B7-H3-expressing tumors ...
GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021 PR Newswire BEVERLY HILLS, Calif. , Nov. 30, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "C...
GT BioPharma to Host a Management Update Conference Call - Tuesday, November 30th at 4:30PM Eastern Time PR Newswire BEVERLY HILLS, Calif. , Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology...
GT Biopharma is an early-stage oncology company with one clinical asset. GT Biopharma will likely shift focus to their 2nd generation therapies, which are still preclinical. Lack of meaningful positive catalysts in the next year reduces attractiveness of investment. For furt...
GT Biopharma (NASDAQ:GTBP): Q3 GAAP EPS of -$0.17 beats by $0.04. Cash and cash equivalents of $35.8M. Press Release For further details see: GT Biopharma EPS beats by $0.04
News, Short Squeeze, Breakout and More Instantly...
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025 GTB-5550 TriKE ® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025 GTB-5550 Phase 1 dose escalation basket trial initiation expected in 20...
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purcha...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...